How hepatitis C virus counteracts the interferon response: The jury is still out on NS5A

Virology

Volumn 284, Issue 1, 2001, Pages 1-12

  Tan, Seng Lai ^a   Katze, Michael G ^b,c  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

E2; Hepatitis C virus; Interferon; JAK STAT pathway; NS5A; PKR

Indexed keywords

NONSTRUCTURAL PROTEIN 5A; RECOMBINANT INTERFERON; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANTIVIRAL ACTIVITY; EFFECTOR CELL; HEPATITIS C; HEPATITIS C VIRUS; IMMUNOPATHOGENESIS; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION; VIRUS REPLICATION;

ANIMALIA; HEPATITIS C VIRUS;

EID: 0035947270     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.2001.0885     Document Type: Article

References (111)

1. Aizaki H., Saito S., Ogino T., Miyajima N., Harada T., Matsuura Y., Miyamura T., Kohase M. Suppression of interferon-induced antiviral activity in cells expressing hepatitis C virus proteins. J. Interferon Cytokine Res. 20:2000;1111-1120.
2. Alcami A., Koszinowski U. H. Viral mechanisms of immune evasion. Trends Microbiol. 8:2000;410-418.
3. Alter M. J., Kruszon-Moran D., Nainan O. V., Mcquillan G. M., Gao F., Moyer L. A., Kaslow R. A., Margolis H. S. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N. Engl. J. Med. 314:1999;556-562.
4. Arima N., Kao C-y., Licht T., Padmanabhan R., Sasaguri Y., Padmanabhan R. Modulation of cell growth by the hepatitis C virus nonstructural protein NS5A. J. Biol. Chem. 2001.
5. Balachandran S., Roberts P. C., Kipperman T., Bhalla K. N., Compans R. W., Archer D. R., Barber G. N. Alpha/beta interferons potentiate virus-induced apoptosis through activation of the FADD/Caspase-8 death signaling pathway. J. Virol. 74:2000;1513-1523.
6. Barnard P., McMillan N. A. The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon-alpha. Virology. 259:1999;305-313.
7. Bartenschlager R., Lohmann V. Replication of hepatitis C virus. J. Gen. Virol. 81:2000;1631-1648.
8. Battaglia A. M., Hagmeyer K. O. Combination therapy with interferon and ribavirin in the treatment of chronic hepatitis C infection. Ann. Pharmacother. 34:2000;487-494.
9. Berg T., Mas Marques A., Hohne M., Wiedenmann B., Hopf U., Schreier E. Mutations in the E2-PePHD and NS5A region of hepatitis C virus type 1 and the dynamics of hepatitis C viremia decline during interferon alfa treatment. Hepatology. 32:2000;1386-1395.
10. Bhattacharya S., Eckner R., Grossman S., Oldread E., Arany Z., D'Andrea A., Livingston D. M. Cooperation of Stat2 and p300/CBP in signaling induced by interferon-alpha. Nature. 383:1996;344-347.
11. Biron C. A. Role of early cytokines, including alpha and beta interferons (IFN-α/β), in innate and adaptive immune responses to viral infections. Semin. Immunol. 10:1998;383-390.
12. Blight K. J., Kolykhalov A. A., Rice C. M. Efficient initiation of HCV RNA replication in cell culture. Science. 290:2000;1972-1975.
13. Borden E. C., Parkinson D. A perspective on the clinical effectiveness and tolerance of interferon-α Semin. Oncol. 25:1998;3-8.
14. Bukh J., Miller R., Purcell R. Genetic heterogeneity of hepatitis C virus: Quasispecies and genotypes. Semin. Liver Dis. 15:1995;41-63.
15. Cebulla C. M., Miller D. M., Sedmak D. D. Viral inhibition of interferon signal transduction. Intervirology. 42:1999;325-330.
16. Chang Y. E, Laimins L. A. Microarray analysis identifies interferon-inducible genes and Stat-1 as major transcriptional targets of human papillomavirus type 31. J. Virol. 74:2000;4174-4182.
17. Chayama K., Suzuki F., Tsubota A., Kobayashi M., Arase Y., Saitoh S., Suzuki Y., Murashima N., Ikeda K., Takahashi N., Kinoshita M., Kumada H. Association of amino acid sequence in the PKR-eIF2 phosphorylation homology domain and response to interferon therapy. Hepatology. 32:2000;1138-1144.
18. Chung J., Uchida I., Grammer T. C., Blenis J. STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation. Mol. Cell. Biol. 17:1997;6508-6516.
19. Chung K. M., Lee J., Kim J.-E., Song O.-K., Cho S., Lim J., Seedorf M., Hahm B., Jang S. K. Nonstructural protein 5A of hepatitis C virus inhibits the function of karyopherin beta3. J. Virol. 74:2000;5233-5241.
20. Cochrane A., Orr A., Shaw M. L., Mills P. R., McCruden E. A. The amino acid sequence of the PKR-eIF2alpha phosphorylation homology domain of hepatitis C virus envelope 2 protein and response to interferon-alpha. J. Infect. Dis. 182:2000;1515-1518.
21. Colamonici O. R., Domanski P., Sweitzer S. M., Larner A., Buller R. M. Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon alpha transmembrane signaling. J. Biol. Chem. 270:1995;15974-15978.
22. Darnell J. E. STATs and gene regulation. Science. 277:1997;1630-1635.
23. David M., Petricoin E., Benjamin C., Pine R., Weber M. J., Larner A. C. Requirement for MAP kinase (ERK2) activity in interferon α- and interferon β-stimulated gene expression through STAT proteins. Science. 269:1995;1721-1723.
24. David M., Wong L., Flavell R., Thompson S. A., Wells A., Larner A. C., Johnson G. R. STAT activation by epidermal growth factor (EGF) and amphiregulin. J. Biol. Chem. 271:1996;9185-9188.
25. Di Bisceglie A. M. Hepatitis C. Lancet. 351:1998;351-355.
26. Durbin J. E., Hackenmiller R., Simon M. C., Levy D. E. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell. 84:1996;443-450.
27. Enomoto N., Sakuma I., Asahina Y., Kurosaki M., Murakami T., Yamamoto C., Izumi N., Marumo F., Sato C. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J. Clin. Invest. 96:1995;224-230.
28. Enomoto N., Sakuma I., Asahina Y., Kurosaki M., Murakami T., Yamamoto C., Ogura Y., Izumi N., Maruno F., Sato C. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N. Engl. J. Med. 334:1996;77-81.
29. Ezelle H. J., Balachandran S., Sicheri F., Polyak S. J., Barber G. N. Analyzing the mechanisms of interferon-induced apoptosis using CrmA and hepatitis C virus NS5A. Virology. 281:2001;124-137.
30. Foster G. R., Ackrill A. M., Goldin R. D., Kerr I. M., Thomas H. C., Stark G. R. Expression of the terminal protein region of hepatitis B virus inhibits cellular responses to interferons alpha and gamma and double-stranded RNA. Proc. Natl. Acad. Sci. USA. 88:1991;2888-2892.
31. Francois C., Duverlie G., Rebouillat D., Khorsi H., Castelain S., Blum H. E., Gatignol A., Wychowski C., Moradpour D., Meurs E. F. Expression of hepatitis C virus proteins interferes with the antiviral action of interferon independently of PKR-mediated control of protein synthesis. J. Virol. 74:2000;5587-5596.
32. Frese M., Pietschmann T., Moradpour D., Haller O., Bartenschlager R. Interferon-a inhibits hepatitis C virus subgenomics RNA replication by an MxA-independent pathway. J. Gen. Virol. 82:2001;723-733.
33. Fukuma T., Enomoto N., Marumo F., Sato C. Mutations in the interferon-sensitivity determining region of hepatitis C virus and transcriptional activity of the nonstructural region 5A protein. Hepatology. 28:1998;1147-1153.
34. Gale M. Jr., Korth M. J., Tang N. M., Tan S.-L., Hopkins D. A., Dever T. E., Polyak S. J., Gretch D. R., Katze M. G. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology. 230:1997;217-227.
35. Gale M. Jr., Blakely C. M., Kwieciszewski B., Tan S.-L., Dossett M., Korth M. J., Polyak S. J., Gretch D. R., Katze M. G. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: Molecular mechanisms of kinase regulation. Mol. Cell. Biol. 18:1998a;5208-5218.
36. Gale M. J. Jr., Katze M. G. Molecular mechanisms of interferon resistance mediated by viral-directed inhibition of PKR, the interferon-induced protein kinase. Pharmacol. Ther. 78:1998b;29-46.
37. Gale M. J. Jr., Kwieciszewski B., Dossett M., Nakao H., Katze M. G. Antiapoptotic and oncogenic potentials of hepatitis C virus are linked to interferon resistance by viral repression of the PKR protein kinase. J. Virol. 73:1999;6506-6516.
38. Gale M., Tan S. L., Katze M. G. Translational control of viral gene expression in eukaryotes. Microbiol. Mol. Biol. Rev. 64:2000;239-280.
39. Gale M. J. Jr., Beard M. R. Molecular clones of hepatitis C virus: Applications to animal models. ILAR J. 42:2001;138-147.
40. Garcin D., Curran J., Kolakofsky D. Sendai virus C proteins must interact directly with cellular components to interfere with interferon action. J. Virol. 74:2000;8823-8830.
41. Ghosh A. K., Steele R., Meyer K., Ray R., Ray R. B. Hepatitis C virus NS5A protein modulates cell cycle regulatory genes and promotes cell growth. J. Gen. Virol. 80:1999;1179-1183.
42. Ghosh A. K., Majumder M., Steele R., Meyer K., Ray R., Ray R. B. Hepatitis C virus NS5A protein protects against TNF-α mediated apoptotic cell death. Virus Res. 67:2000;173-178.
43. Ghosh A. K., Majumder M., Steele R., Yaciuk P., Chrivia J., Ray R., Ray R. B. Hepatitis C virus NS5A protein modulates transcription through a novel cellular transcription factor SRCAP. J. Biol. Chem. 275:2000;7184-7188.
44. Gil J., Esteban M. The interferon-induced protein kinase (PKR), triggers apoptosis through FADD-mediated activation of caspase 8 in a manner independent of Fas and TNF-alpha receptors. Oncogene. 19:2000;3665-3674.
45. Goh K. C., Haque S. J., Williams B. R. p38 MAP kinase is required for STAT1 serine phosphorylation and transcriptional activation induced by interferons. EMBO J. 18:1999;5601-5608.
46. Goh K. C., deVeer M. J., Williams B. R. The protein kinase PKR is required for p38 MAPK activation and the innate immune response to bacterial endotoxin. EMBO J. 19:2000;4292-4297.
47. He, Y, Nakao, H, Tan, S-L, Vijaysri, S, Jacobs, B. L, and, Katze, M. G. Subversion of host signaling pathways by hepatitis C virus via NS5A association with Grb2 and Gab1. Manuscript in preparation.
48. He Y., Tan S-L., Tareen S. U., Vijaysri S., Langland J. O., Jacobs B. L., Katze M. G. Regulation of mRNA translation and cellular signaling by hepatitis C virus NS5A nonstructural protein. J. Virol. 2001.
49. Heim M. H., Moradpour D., Blum H. E. Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway. J. Virol. 73:1999;8469-8475.
50. Herion D., Hoofnagle J. The interferon sensitivity determining region: All hepatitis C virus isolates are not the same. Hepatology. 25:1997;769-771.
51. Hijikata M., Mizushima H., Tanji Y., Komoda Y., Hirowatari Y., Akagi T., Kato N., Kimura K., Shimotohno K. Proteolytic processing and membrane association of putative nonstructural proteins of hepatitis C virus. Proc. Natl. Acad. Sci. USA. 90:1993;10773-10777.
52. Hoofnagle J. H. Management of hepatitis C: Current and future perspectives. J. Hepatol. 31:1999;264-268.
53. Ide Y., Zhang L., Chen M., Inchauspe G., Bahl C., Sasaguri Y., Padmanabhan R. Characterization of the nuclear localization signal and subcellular distribution of hepatitis C virus nonstructural protein NS5A. Gene. 182:1996;203-211.
54. Ide Y., Tanimoto A., Sasaguri Y., Padmanabhan R. Hepatitis C virus NS5A protein is phosphorylated in vitro by a stably bound protein kinase from HeLa cells and by cAMP-dependent protein kinase A-alpha catalytic subunit. Gene. 201:1997;151-158.
55. 2-terminal kinase by double-stranded RNA and encephalomyocarditis virus: involvement of RNase L, protein kinase R, and alternative pathways. Mol. Cell. Biol. 20:2000;617-627.
56. Jain N., Zhang T., Fong S. L., Lim C. P., Cao X. Repression of Stat3 activity by activation of mitogen-activated protein kinase (MAPK). Oncogene. 17:1998;3157-3167.
57. Kaneko T., Tanji Y., Satoh S., Hijikata M., Asabe S., Kimura K., Shimotohno K. Production of two phosphoproteins from the NS5A region of the hepatitis C viral genome. Biochem. Biophys. Res. Commun. 205:1994;320-326.
58. Kato N., Lan K. H., Ono-Nita S. K., Shiratori Y., Omata M. Hepatitis C virus nonstructural region 5A protein is a potent transcriptional activator. J. Virol. 71:1997;8856-8859.
59. Katze M. G., Kwieciszewski B., Goodlett D. R., Blakely C. M., Neddermann P., Tan S. L., Aebersold R. Ser(2194) is a highly conserved major phosphorylation site of the hepatitis C virus nonstructural protein NS5A. Virology. 278:2000;501-513.
60. Kaufman R. J. Double-stranded RNA-activated protein kinase PKR. Sonenberg N., Hershey J. W. B., Mathews M. B. Translational Control of Gene Expression. 2000;503-528 Cold Spring Harbor Laboratory Press, Cold Spring Harbor.
61. Keskinen P., Nyqvist M., Sareneva T., Pirhonen J., Melen K., Julkunen I. Impaired antiviral response in human hepatoma cells. Virology. 263:1999;364-375.
62. Khabar K. S., Al-Zoghaibi F., Al-Ahdal M. N., Murayama T., Dhalla M., Mukaida N., Taha M., Al-Sedairy S. T., Siddiqui Y., Kessie G., Matsushima K. The alpha chemokine, interleukin 8, inhibits the antiviral action of interferon alpha. J. Exp. Med. 186:1997;1077-1085.
63. Kim J., Lee D., Choe J. Hepatitis C virus NS5A protein is phosphorylated by casein kinase II. Biochem. Biophys. Res. Commun. 257:1999;777-781.
64. Komatsu T., Takeuchi K., Yokoo J., Tanaka Y., Gotoh B. Sendai virus blocks alpha interferon signaling to signal transducers and activators of transcription. J. Virol. 74:2000;2477-2480.
65. Korth M. J., Katze M. G. Evading the interferon response: Hepatitis C virus and the interferon-induced protein kinase, PKR. Curr. Top. Microbiol. Immunol. 242:1999;197-224.
66. Lee S. B., Rodriguez D., Rodriguez J. R., Esteban M. The apoptosis pathway triggered by the interferon-induced protein kinase PKR requires the third basic domain, initiates upstream of Bcl-2, and involves ICE-like proteases. Virology. 231:1997;81-88.
67. Leaman D. W., Leung S., Li X., Stark G. R. Regulation of STAT-dependent pathways by growth factors and cytokines. FASEB J. 10:1996;1578-1588.
68. Leonard G. T., Sen G. C. Effects of adenovirus E1A protein on interferon-signaling. Virology. 224:1996;25-33.
69. Leonard G. T., Sen G. C. Restoration of interferon responses of adenovirus E1A-expressing HT1080 cell lines by overexpression of p48 protein. J. Virol. 71:1997;5095-5101.
70. Li S., Labrecque S., Gauzzi M. C., Cuddihy A. R., Wong A. H., Pellegrini S., Matlashewski G. J., Koromilas A. E. The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-alpha. Oncogene. 18:1999;5727-5737.
71. Lohmann V., Körner F., Koch J.-O., Herian U., Theilmann L., Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science. 285:1999;110-113.
72. Lohmann V., Korner F., Dobierzewska A., Bartenschlager R. Mutations in hepatitis C virus RNAs conferring cell culture adaptation. J. Virol. 75:2001;1437-1449.
73. Manger I. D., Relman D. A. How the host 'sees' pathogens: Global gene expression responses to infection. Curr. Opin. Immunol. 12:2000;215-218.
74. Manns M. P., Rambusch E. G. Autoimmunity and extrahepatic manifestations in hepatitis C virus infection. J. Hepatol. 31:1999;39-42.
75. Majumder M., Ghosh A. K., Steele R., Ray R., Ray R. B. Hepatitis C virus NS5A physically associates with p53 and regulates p21/waf1 gene expression in a p53-dependent manner. J. Virol. 75:2001;1401-1407.
76. McHutchison J. G., Gordon S. C., Schiff E. R., Shiffman M. L., Lee W. M., Goodman Z. D., Ling M. H., Cort S., Albrecht J. K. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med. 339:1998;1485-1492.
77. Melen K., Keskinen P., Lehtonen A., Julkunen I. Interferon-induced gene expression and signaling in human hepatoma cell lines. J. Hepatol. 33:2000;764-772.
78. Miller D. M., Rahill B. M., Boss J. M., Lairmore M. D., Durbin J. E., Waldman J. W., Sedmak D. D. Human cytomegalovirus inhibits major histocompatibility complex class II expression by disruption of the Jak/Stat pathway. J. Exp. Med. 187:1998;675-683.
79. Moradpour D., Kary P., Rice C. M., Blum H. E. Continuous human cell lines inducibly expressing hepatitis C virus structural and nonstructural proteins. Hepatology. 28:1998;192-201.
80. Mossman K. L., Macgregor P. F., Rozmus J. J., Goryachev A. B., Edwards A. M., Smiley J. R. Herpes simplex virus triggers and then disarms a host antiviral response. J. Virol. 75:2001;750-758.
81. Paterson M., Laxton C. D., Thomas H. C., Ackrill A. M., Foster G. R. Hepatitis C virus NS5A protein inhibits interferon antiviral activity, but the effects do not correlate with clinical response. Gastroenterology. 117:1999;1187-1197.
82. Patzwahl R., Meier V., Ramadori G., Mihm S. Enhanced expression of interferon-regulated genes in the liver of patients with chronic hepatitis C virus infection: Detection by suppression-subtractive hybridization. J. Virol. 75:2001;1332-1338.
83. Pawlotsky J. M. Hepatitis C virus resistance to antiviral therapy. Hepatology. 32:2000;889-896.
84. Pietschmann T., Lohmann V., Rutter G., Kurpanek K., Bartenschlager R. Characterization of cell lines carrying self-replicating hepatitis C virus RNAs. J. Virol. 75:2001;1252-1264.
85. Polyak S. J., Paschal D. M., McArdle S., Gale M. J. Jr., Moradpour D., Gretch D. R. Characterization of the effects of hepatitis C virus nonstructural 5A protein expression in human cell lines and on interferon-sensitive virus replication. Hepatology. 29:1999;1262-1271.
86. Polyak S. J., Nousbaum J. B., Larson A. M., Cotler S., Carithers R. L., Gretch D. R. The protein kinase-interacting domain in the hepatitis C virus envelope glycoprotein-2 gene is highly conserved in genotype 1-infected patients treated with interferon. J. Infect. Dis. 182:2000;397-404.
87. Polyak S. J., Khabar K. S. A., Paschal D. M., Ezelle H. J., Rezeiq M., Duverlie G., Barber G. N., Levy D. E., Mukaida N., Gretch D. R. The hepatitis C virus non-structural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response. J. Virol. 2001.
88. Reed K. E., Rice C. M. Identification of the major phosphorylation site of the hepatitis C virus H strain NS5A protein as serine 2321. J. Biol. Chem. 274:1999;28011-28018.
89. Reed K. E., Rice C. M. Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. Curr. Top. Microbiol. Immunol. 242:2000;55-84.
90. Sarrazin C., Kornetzky I., Ruster B., Lee J. H., Kronenberger B., Bruch K., Roth W. K., Zeuzem S. Mutations within the E2 and NS5A protein in patients infected with hepatitis C virus type 3a and correlation with treatment response. Hepatology. 31:2000;1360-1370.
91. Satoh S., Hijikata M., Handa H., Shimotohno K. Caspase-mediated cleavage of eukaryotic translation initiation factor subunit 2alpha. Biochem. J. 342:1999;65-70.
92. Satoh S., Hirota M., Noguchi T., Hijikata M., Handa H., Shimotohno K. Cleavage of hepatitis C virus nonstructural protein 5A by a caspase-like protease(s) in mammalian cells. Virology. 270:2000;476-487.
93. Song J., Fuji S. J., Wang F., Itoh M., Hotta H. The NS5A protein of hepatitis C virus partially inhibits the antiviral activity of interferon. J. Gen. Virol. 80:1999;879-886.
94. Song J., Nagano-Fujii M., Wang F., Florese R., Fujita T., Ishido S., Hotta H. Nuclear localization and intramolecular cleavage of N-terminally deleted NS5A protein of hepatitis C virus. Virus Res. 69:2000;109-117.
95. Stark G. R., Kerr I. M., Williams B. R. G., Silverman R. H., Schreiber R. D. How cells respond to interferons. Annu. Rev. Biochem. 67:1998;227-264.
96. Tan S.-L., Katze M. G. The emerging role of the interferon-induced PKR protein kinase as an apoptotic effector: A new face of death? J. Interferon Cytokine Res. 19:1999;545-556.
97. Tan S.-L., Nakao H., He Y., Vijaysri V., Neddermann P., Jacobs B. L., Mayer B. J, Katze M. G. NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/ligand-dependent manner and perturbs mitogenic signaling. Proc. Natl. Acad. Sci. USA. 96:1999;5533-5538.
98. Taniguchi T., Lamphier M. S., Tanaka N. IRF-1: The transcription factor linking the interferon response and oncogenesis. Biochim. Biophys. Acta. 1333:1997;9-17.
99. Tanimoto A., Ide Y., Arima N., Sasaguri Y., Padmanabhan R. The amino terminal deletion mutants of hepatitis C virus nonstructural protein NS5A function as transcriptional activators in yeast. Biochem. Biophys. Res. Commun. 236:1997;360-364.
100. Taylor D. R., Tian B., Romano P. R., Hinnebusch A. G., Lai M. M., Mathews M. B. Hepatitis C virus envelope protein E2 does not inhibit PKR by simple competition with autophosphorylation sites in the RNA-binding domain. J. Virol. 75:2001;1265-1273.
101. Taylor D. R., Shi S. T., Romano P. R., Barber G. N., Lai M. M. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science. 285:1999;107-110.
102. Vilcek J., Sen G. Interferons and other cytokines. Fields B. N., Knipe D. M., Howley P. M. Fields Virology. 1996;375-399 Lippincott-Raven, Philadelphia.
103. Weihua X., Ramanujam S., Lindner D. J., Kudaravalli R. D., Freund R., Kalvakolanu D. V. The polyoma virus T antigen interferes with interferon-inducible gene expression. Proc. Natl. Acad. Sci. USA. 95:1998;1085-1090.
104. Wen Z., Zhong Z., Darnell J. E. Jr. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell. 82:1995;241-250.
105. Williams B. R. G. PKR: A sentinel kinase for cellular stress. Oncogene. 18:1999;6112-6120.
106. Winston L. A., Hunter T. Intracellular signaling: Putting JAKs on the kinase MAP. Curr. Biol. 6:1996;668-671.
107. Witherell G. W., Beineke P. Statistical analysis of combined substitutions in nonstructural 5A region of hepatitis C virus and interferon response. J. Med. Virol. 63:2001;8-16.
108. Young D. F., Didcock L., Goodbourn S., Randall R. E. Paramyxoviridae use distinct virus-specific mechanisms to circumvent the interferon response. Virology. 269:2000;383-390.
109. Zhang X., Blenis J., Li H. C., Schindler C., Chen-Kiang S. Requirement of serine phosphorylation for formation of STAT-promoter complexes. Science. 267:1995;1990-1994.
110. Zhu H., Cong J. P., Shenk T. Use of differential display analysis to assess the effect of human cytomegalovirus infection on the accumulation of cellular RNAs: Induction of interferon-responsive RNAs. Proc. Natl. Acad. Sci. USA. 94:1997;13985-13990.
111. Zimring J. C., Goodbourn S., Offermann M. K. Human herpesvirus 8 encodes an interferon regulatory factor (IRF) homolog that represses IRF-1-mediated transcription. J. Virol. 72:1998;701-707.